Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2021-04-16 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
独立董事对担保等事项的独立意见
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Directors 2020 Annual Report Special Explanation and Independent Opinions" for Jiangsu Sihuan Bioengineering Co., Ltd. It contains detailed independent opinions on related party transactions, external guarantees, internal control evaluation report, profit distribution proposal, audit report with emphasis paragraphs, and asset impairment provisions for the fiscal year 2020. The content is a formal independent directors' report providing opinions on the company's annual financial and governance matters, which is typical of an Audit Report / Information filing rather than the full Annual Report (10-K) or a simple announcement. The document length is 1753 characters, which is relatively short but contains substantive independent audit-related opinions and explanations, not just an announcement or certification. Therefore, it fits best under the Audit Report / Information (AR) category. FY 2020
2021-04-16 Chinese
内部控制鉴证报告
Regulatory Filings
2021-04-16 Chinese
2020年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2020 年年度报告全文" which translates to "2020 Annual Report Full Text" for 江苏四环生物股份有限公司. It contains detailed financial data, business overview, management discussion and analysis, financial statements, auditor's report mention, and other comprehensive information typical of a full annual report. The length is substantial (15,000 characters), and it includes audited financial data, management commentary, and detailed disclosures. There is no indication that this is merely an announcement or a summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2020
2021-04-16 Chinese
江苏四环生物股份有限公司独立董事2020年度述职报告(廖述斌）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2020 by an independent director of Jiangsu Sihuan Bio Co., Ltd. It details the director's attendance at board meetings, opinions on various board matters, communication with management, and efforts to protect investor rights. The content focuses on the director's duties and oversight rather than presenting financial statements or audit results. The document length is short (1372 characters), and it is a narrative report of the independent director's activities and opinions rather than a formal audit report or annual report. This fits best under the category of Board/Management Information (MANG), which includes announcements related to board members and their activities. It is not an audit report (AR) because it does not contain audit opinions or financial statement audits, nor is it a full annual report (10-K).
2021-04-16 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board meeting of Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. It details the approval of the 2020 Annual Report, Supervisory Board Work Report, Financial Statements, Profit Distribution Plan, Internal Control Evaluation Report, and other related matters. The document is short (1295 characters) and primarily announces the passing of these reports and proposals, which will be submitted to the shareholders' meeting for approval. It does not contain the full annual report or detailed financial statements itself but rather the resolutions from the Supervisory Board meeting. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official announcement of meeting resolutions and approvals, not the full Annual Report (10-K) or other detailed reports.
2021-04-16 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the company's ninth board meeting, detailing the approval of various reports and proposals related to the 2020 fiscal year, including the annual report, board work report, financial statements, profit distribution plan, remuneration, internal control evaluation, and audit report explanations. It explicitly states that the full 2020 annual report and other detailed reports are disclosed elsewhere (on the CNINFO website and newspapers). The document itself is a summary of board resolutions and voting results, not the full annual report or financial statements. The document length is short (1899 characters), and it serves as an announcement of the board's approval of the annual report and related documents, which will be submitted to the shareholders' meeting for approval. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of board resolutions and approvals related to the annual report, not the annual report itself.
2021-04-16 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.